Our Work in Dermatology

Targeted biologics, the recent emergence of innovative new oral therapies, and the arrival of biosimilars will continue to fuel monumental shifts in the way patients with auto-immune disorders are managed. More than ever, for both existing brands & pipeline products, future success will require a deep understanding of this complex and rapidly evolving landscape.

VIEW REPORTS OFFERED IN THIS AREA

Diseases Covered

Atopic Dermatitis, Psoriasis

Board of Advisors

Coming soon.

Advocacy Groups

The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with diseases in dermatology and those who are close to them.

RECENT PUBLICATIONS

Spherix Global Insights Reports Sun Dermatology’s Ilumya Faces Challenges in A Crowded Psoriasis Market – December 5, 2018
>VIEW ARTICLE

Spherix Global Insights’ Annual Update of the Psoriasis Switching Market Reveals Significant Gains for Janssen’s Tremfya, Much to the Detriment of Sister-Brand Stelara – November 20, 2018
>VIEW ARTICLE

Sanofi/Regeneron’s Dupixent Continues to Flourish as the Only Atopic Dermatitis Game in Town, but US Dermatologists Identify a Gap Between Current Patients and Candidates for Treatment – November 7, 2018
>VIEW ARTICLE

UPCOMING CONFERENCES

Fall Clinical Dermatology Conference
>LEARN MORE

HELPFUL LINKS

AAD logo
American Dermatological Association Logo